on Galimedix, Inc.
Galimedix's GAL-201 Shows Promise in Alzheimer's Treatment
Galimedix Therapeutics has published new data in the International Journal of Molecular Sciences, revealing the potential of GAL-201 in modifying Alzheimer’s disease progression. The study highlights GAL-201's ability to prevent synaptic damage and improve memory and behavior by targeting amyloid-beta (Aβ) pathologies.
GAL-201, currently in preclinical testing, demonstrated significant improvement in learning and memory in animal models. By targeting Aβ aggregation, it effectively reduces the formation of toxic oligomers, resulting in cognitive improvements. The compound also exhibits anti-inflammatory effects and reduces Aβ plaques, addressing key drivers of Alzheimer’s disease.
Galimedix is also developing GAL-101, closely related to GAL-201, currently in a Phase 1 study, with GAL-101 eye drops being investigated for macular degeneration.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news